Compare · ESYN vs MEDS
ESYN vs MEDS
Side-by-side comparison of EnerSyn Global Inc. (ESYN) and DataMeds AI Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESYN and MEDS operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- ESYN is the larger of the two at $48.5M, about 8.5x MEDS ($5.7M).
- MEDS has hit the wire 7 times in the past 4 weeks while ESYN has been quiet.
- MEDS has more recent analyst coverage (1 ratings vs 0 for ESYN).
- Company
- EnerSyn Global Inc.
- DataMeds AI Inc.
- Price
- -
- -
- Market cap
- $48.5M
- $5.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 1
EnerSyn Global Inc.
Previously known as HWH International Inc., the Company operates as a purpose-driven lifestyle company encompassing differentiated offerings to develop new pathways to help people in their pursuit of Health, Wealth and Happiness. The Company's management team has begun to evaluate a range of additional growth and investment opportunities that it believes can build long-term shareholder value and drive strong, sustainable growth. The Company intends to pursue such opportunities selectively and prudently, in a manner management deems beneficial to, and aligned with the long-term interests of its stockholders. The Company believes that energy represents a new addition to the Company that may provide favorable opportunities.
DataMeds AI Inc.
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.
Latest ESYN
No recent items for EnerSyn Global Inc..
Latest MEDS
- DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
- DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
- DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
- DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies
- DataMeds Regains Compliance With NASDAQ Listing Standards
- DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
- DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
- DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division